GALMED PHARMACEUTICALS LTD

GLMDNASDAQ

🏆 #3859 by market capEarnings Nov 25US Equity

$0.56▼ $0.03 (−6.10%)

Live

1h—

24h▼ 6.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$5M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

2.2x

Cheap

Otter Score

Weak

No chart data available for GLMD.

Trading Snapshot

Day Range: $0.55 – $0.56
52-Week Range: $0.41 – $1.65
Volume: $3.20B
Avg Volume: $3.93B
Shares Outstanding: 8.3M
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $527,982
P/E Ratio: —
P/S Ratio: 2.2x
EPS (TTM): $-2.07
Dividend Yield: —

Why Investors Own GLMD

✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +16.7% YoY

Gross Margin (TTM)

26.2%▲ +0.0% YoY

Operating Income (TTM)

$505,326▲ +16.7% YoY

Free Cash Flow (TTM)

$525,813▲ +16.7% YoY

About GALMED PHARMACEUTICALS LTD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

🦦